Advancing Risk-Based Approaches in Blood Pressure Management: Reflections on the 2025 AHA/ACC Statement.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Impact of Total or Afferent Renal-Nerve Denervation on Cardiovascular and Renal Function in Sprague Dawley Rats Fed High-Fructose and High-Sodium Diet.Nutrients · 2026
   Article
2. Why wait? the case for up-front single-pill combination therapy in stage 1 hypertension.Journal of human hypertension · 2026
   Review
3. Implications of the 2025 AHA/ACC hypertension guideline on hypertension prevalence, treatment eligibility and blood pressure control in Nigeria: a cross-sectional comparative study.BMJ public health · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as